All Updates

All Updates

icon
Filter
Product updates
KSQ Therapeutics doses first patient in KSQ-001EX clinical development program
Human Gene Editing
Jun 12, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Human Gene Editing

Human Gene Editing

Jun 12, 2024

KSQ Therapeutics doses first patient in KSQ-001EX clinical development program

Product updates

  • Gene editing-based oncology therapeutics developer KSQ Therapeutics has initiated the first patient treatment in a Phase I/II clinical trial of its new candidate, KSQ-001EX. It is a tumor-infiltrating lymphocyte (TIL) therapy with the SOCS1 gene inactivated by CRISPR/Cas9 gene editing, developed as a potential treatment for various solid tumor conditions.

  • The trial is carried out in two phases: Phase I, evaluating the safety and tolerability of KSQ-001EX, and Phase II, evaluating antitumor activity in indication-specific cohorts. The clinical trial is an open-label, safety lead-in study for patients with melanoma, head-and-neck squamous cell carcinoma (HNSCC), and non-small-cell lung cancer (NSCLC).

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.